|
|
- Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer's disease and Anavex’s Phase I clinical program as "Trial
Sources News Release
Resource Type: Article
Published: 2011
ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.
- ANAVEX 2-73 advances Phase I clinical trial for Alzheimer's disease
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs
- Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
Sources News Release
Resource Type: Article
Published: 2010
Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
- Anavex appoints Dr. Rachelle Doody to Scientific Advisory Board
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product
- Anavex comments on new Alzheimer's disease diagnostic guidelines
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated
- Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer's disease
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer
- Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer's Disease
Sources News Release
Resource Type: Article
Published: 2011
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The
- ART Advanced Research Technologies Inc.
Media Profile in Sources
Resource Type: Organization
- Bad Pharma
How drug companies mislead doctors and harm patients
Resource Type: Book
Published: 2012
Doctors and patients need good scientific evidence to make informed decisions. But instead, companies run bad trials on their own drugs, which distort and exaggerate the benefits by design. When these trials produce unflattering results, the data is simply buried.
- Bad Pharma, Bad Journalism
Resource Type: Article
Published: 2012
‘The drugs don't work: a modern medical scandal’, from Ben Goldacre's new book, Bad Pharma presents a disturbing picture emerges of corporate drug abuse.
- The Body Hunters
Testing New Drugs on the World's Poorest Patients
Resource Type: Book
This is a review on the rise of drug companies as well as the difficulties of medical research ethics. Shaw states that companies make more money developing drugs to treat American heatburn than malaria drugs. Attempts to expose drug companies have failed because of litigation. There is no mention of where and what pharmaceuticals test on the "poorest patients". Her recommendation is that medicines should be regarded as "social goods" and as such.
- Canadian AIDS Treatment Information Exchange (CATIE)
Media Profile in Sources
Resource Type: Organization
- Networks of Centres of Excellence of Canada
Media Profile in Sources
Resource Type: Organization
- Nurses to Fraser Health: Come clean on drug company ties, funding for flu vaccine study
Sources News Release
Resource Type: Article
Published: 2012
The study involving Novartis Pharmaceuticals is headed up by Fraser's chief medical health officer, a key figure driving the policy to force healthcare workers to take the flu vaccine or wear a mask
- Private Profits vs Public Policy
The Pharmaceutical Industry and the Canadian State
Resource Type: Book
Published: 2016
According to Joel Lexchin, "Given the central role that medicines play in keeping us healthy, it is essential that we understand the policy environment that governs drug development, from the initial basic research to the sale of the manufactured produces to the patients that use them."
- The Real Pushers
A Critical Analysis of the Canadian Drug Industry
Resource Type: Book
Published: 1984
A comprehensive analysis of the pharmaceutical drug industry in Canada.
- Sources HotLink - June 30, 2016
Resource Type: Serial Publication (Periodical)
Published: 2016
Articles about the FBI and the information it gathers, Donald Trump and the media, and the role of pharmaceutical companies in suppressing information.
|
AlterLinks
© 2021.
|
|
|
|